文献速递泌尿生殖介入PETCTMR

68Ga标记的前列腺特异性膜抗原PET/CT与多参数MRI在根治性前列腺切除术前排除区域淋巴结转移的比较

A comparison between 68Ga-labeled prostate-specific membrane antigen-PET/CT and multiparametric MRI for excluding regional metastases prior to radical prostatectomy.
PubMed 文献 · Abdom Radiol (NY) · 2020-07-15

该多中心队列研究分析了89例接受根治性前列腺切除术及盆腔淋巴结清扫的患者,比较68Ga-PSMA PET/CT与mpMRI排除淋巴结侵犯的阴性预测值。结果显示两者表现相似,全队列NPV分别约89%和87%,联合检测为90%且未显著提高NPV。作者认为即使采用先进影像,仍推荐行盆腔淋巴结清扫以准确分期,尤其高危人群。

要点

  • PSMA PET/CT与mpMRI排除盆腔淋巴结侵犯的NPV相似,全队列分别约89%和87%。
  • 联合两项检查的NPV为90%,较单 modality 无显著提高。
  • 高危患者中两种影像NPV均较低(80%-82%),漏诊淋巴结中位径仅5.5mm。

关键影像表现/征象

  • PET/CT以68Ga-PSMA摄取增高为阳性,mpMRI以淋巴结增大(>10 mm)或形态异常为阳性。
  • 全队列中,mpMRI、PSMA PET/CT及两者联合的NPV分别为87%、89%和90%。
  • 中危患者中,mpMRI、PSMA PET/CT及联合的NPV分别为95%、97%和97%。
  • 高危患者中,mpMRI、PSMA PET/CT及联合的NPV分别为80%、82%和83%。
  • 两种影像均漏诊的淋巴结中位直径为5.5 mm(IQR 3-10),淋巴结内肿瘤中位直径为1 mm(IQR 1-3)。

诊断标准与关键数值

  • PET/CT阳性标准:68Ga-PSMA摄取增高。
  • mpMRI阳性标准:淋巴结增大(>10 mm)或形态异常。
  • 参考标准:最终手术病理。
  • 全队列NPV:mpMRI 87%、PSMA PET/CT 89%、联合90%。
  • 中危患者NPV:mpMRI 95%、PSMA PET/CT 97%、联合97%;高危患者NPV:mpMRI 80%、PSMA PET/CT 82%、联合83%。

临床应用与阅片要点

  • 在报告术前分期时,应注明PSMA PET/CT和mpMRI对盆腔淋巴结侵犯的阴性预测值分别约89%和87%,联合约90%。
  • 对于高危患者,即使影像阴性,仍应提示盆腔淋巴结清扫的必要性,因NPV仅80%-83%。
  • 需注意两种影像可能漏诊直径约5.5 mm的淋巴结转移灶。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To compare the ability of 68Ga -PSMA PET/CT (PSMA PET/CT) and multiparametric MRI (mpMRI) to exclude lymph node invasion (LNI) in patients who undergo radical prostatectomy (RP).

MATERIALS AND METHODS: A multicenter cohort of patients who underwent PSMA PET/CT and pelvic mpMRI prior to RP with pelvic lymph node dissection (PLND) was analyzed. Increased Ga68-PSMA uptake on PET/CT and enlarged (> 10 mm) or abnormal lymph nodes on mpMRI were considered positive findings. The final surgical pathology served as the standard of reference. The negative predictive value (NPV) was calculated for each modality separately, as well as the combined value.

RESULTS: Included were 89 patients with D'Amico intermediate (45%) or high-risk (55%) prostate cancer. The median number of extracted LN was 9 (IQR 6-14). LNI was found in 12 (13.5%) patients. The NPV of mpMRI, PSMA PET/CT, and the two tests combined were 87%, 89%, and 90%, in the entire cohort, 95%, 97%, and 97% in patients with intermediate-risk disease, and 80%, 82%, and 83% in patients with high-risk disease, respectively. The median diameter of LN missed by both imaging and the median intranodal tumor diameter was 5.5 (IQR 3-10) mm and 1 (IQR 1-3) mm, respectively.

CONCLUSIONS: PSMA PET/CT and mpMRI demonstrated similar performance in excluding pelvic LNI with NPV of approximately 90%. The combination of both tests does not improve NPV significantly. Therefore, even in the era of advanced imaging, PLND is still recommended for accurate staging, especially in the high-risk population.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Frumer M, Milk N, Rinott Mizrahi G, et al. A comparison between 68Ga-labeled prostate-specific membrane antigen-PET/CT and multiparametric MRI for excluding regional metastases prior to radical prostatectomy. Abdom Radiol (NY). 2020. PMID: 32671440. doi:10.1007/s00261-020-02640-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。